Researchers presented clinical-trial data showing that Ozempic (semaglutide) reduces kidney failure risk by 24% and death by 20% for type 2 diabetes patients with chronic kidney disease.
Novo Nordisk halted its kidney-disease trial due to overwhelmingly positive results making it unethical to continue giving placebos, indicating significant benefits of Ozempic (semaglutide).
[
add
]
[
|
|
...
]